206 related articles for article (PubMed ID: 16000578)
1. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.
Scott AM; Lee FT; Jones R; Hopkins W; MacGregor D; Cebon JS; Hannah A; Chong G; U P; Papenfuss A; Rigopoulos A; Sturrock S; Murphy R; Wirth V; Murone C; Smyth FE; Knight S; Welt S; Ritter G; Richards E; Nice EC; Burgess AW; Old LJ
Clin Cancer Res; 2005 Jul; 11(13):4810-7. PubMed ID: 16000578
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
Chong G; Lee FT; Hopkins W; Tebbutt N; Cebon JS; Mountain AJ; Chappell B; Papenfuss A; Schleyer P; U P; Murphy R; Wirth V; Smyth FE; Potasz N; Poon A; Davis ID; Saunder T; O'keefe GJ; Burgess AW; Hoffman EW; Old LJ; Scott AM
Clin Cancer Res; 2005 Jul; 11(13):4818-26. PubMed ID: 16000579
[TBL] [Abstract][Full Text] [Related]
3. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
[TBL] [Abstract][Full Text] [Related]
4. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.
Welt S; Ritter G; Williams C; Cohen LS; Jungbluth A; Richards EA; Old LJ; Kemeny NE
Clin Cancer Res; 2003 Apr; 9(4):1347-53. PubMed ID: 12684403
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
[TBL] [Abstract][Full Text] [Related]
6. Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine.
Herbertson RA; Tebbutt NC; Lee FT; Gill S; Chappell B; Cavicchiolo T; Saunder T; O'Keefe GJ; Poon A; Lee ST; Murphy R; Hopkins W; Scott FE; Scott AM
J Nucl Med; 2014 Apr; 55(4):534-9. PubMed ID: 24556590
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of anticolon cancer humanized antibody A33.
Welt S; Ritter G; Williams C; Cohen LS; John M; Jungbluth A; Richards EA; Old LJ; Kemeny NE
Clin Cancer Res; 2003 Apr; 9(4):1338-46. PubMed ID: 12684402
[TBL] [Abstract][Full Text] [Related]
8. A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma.
Sakamoto J; Oriuchi N; Mochiki E; Asao T; Scott AM; Hoffman EW; Jungbluth AA; Matsui T; Lee FT; Papenfuss A; Kuwano H; Takahashi T; Endo K; Old LJ
Cancer Sci; 2006 Nov; 97(11):1248-54. PubMed ID: 17034367
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
[TBL] [Abstract][Full Text] [Related]
10. Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.
Hajjar G; Sharkey RM; Burton J; Zhang CH; Yeldell D; Matthies A; Alavi A; Losman MJ; Brenner A; Goldenberg DM
Clin Colorectal Cancer; 2002 May; 2(1):31-42. PubMed ID: 12453334
[TBL] [Abstract][Full Text] [Related]
11. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
Wong JY; Chu DZ; Williams LE; Yamauchi DM; Ikle DN; Kwok CS; Liu A; Wilczynski S; Colcher D; Yazaki PJ; Shively JE; Wu AM; Raubitschek AA
Clin Cancer Res; 2004 Aug; 10(15):5014-21. PubMed ID: 15297402
[TBL] [Abstract][Full Text] [Related]
12. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
13. Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors.
Delaloye AB; Delaloye B; Buchegger F; Vogel CA; Gillet M; Mach JP; Smith A; Schubiger PA
J Nucl Med; 1997 Jun; 38(6):847-53. PubMed ID: 9189128
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of the chimeric monoclonal antibody (c30.6) in patients with metastatic colorectal cancer.
Ward RL; Packham D; Smythe AM; Murray J; Anderson-Stewart P; Kitchen N; Muirhead R; Phillips P; Gray P; Bigg-Wither G; Prabakaran K; Freund J; Fullham M; Rule M; Dalley D; Meagher A; Hawkins NJ; Smith GM
Clin Cancer Res; 2000 Dec; 6(12):4674-83. PubMed ID: 11156219
[TBL] [Abstract][Full Text] [Related]
15. Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody.
Lee FT; Hall C; Rigopoulos A; Zweit J; Pathmaraj K; O'Keefe GJ; Smyth FE; Welt S; Old LJ; Scott AM
J Nucl Med; 2001 May; 42(5):764-9. PubMed ID: 11337573
[TBL] [Abstract][Full Text] [Related]
16. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Ying Z; Zhang CH; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Mar; 38(3):409-18. PubMed ID: 9074529
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
Sharkey RM; Hajjar G; Yeldell D; Brenner A; Burton J; Rubin A; Goldenberg DM
J Nucl Med; 2005 Apr; 46(4):620-33. PubMed ID: 15809485
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer.
Infante JR; Bendell JC; Goff LW; Jones SF; Chan E; Sudo T; Burris HA; Berlin JD
Eur J Cancer; 2013 Apr; 49(6):1169-75. PubMed ID: 23294608
[TBL] [Abstract][Full Text] [Related]
19. (124)I-huA33 antibody PET of colorectal cancer.
Carrasquillo JA; Pandit-Taskar N; O'Donoghue JA; Humm JL; Zanzonico P; Smith-Jones PM; Divgi CR; Pryma DA; Ruan S; Kemeny NE; Fong Y; Wong D; Jaggi JS; Scheinberg DA; Gonen M; Panageas KS; Ritter G; Jungbluth AA; Old LJ; Larson SM
J Nucl Med; 2011 Aug; 52(8):1173-80. PubMed ID: 21764796
[TBL] [Abstract][Full Text] [Related]
20. Influence of size, surface, cell line, and kinetic properties on the specific binding of A33 antigen-targeted multilayered particles and capsules to colorectal cancer cells.
Cortez C; Tomaskovic-Crook E; Johnston AP; Scott AM; Nice EC; Heath JK; Caruso F
ACS Nano; 2007 Sep; 1(2):93-102. PubMed ID: 19206525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
